Showing 4211-4220 of 5646 results for "".
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials
- MacuLogix Reaches Milestone with One Million Dark Adaptation Testshttps://modernod.com/news/maculogix-reaches-milestone-with-one-million-dark-adaptation-tests/2480853/MacuLogix announced that more than 1 million dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia. Both devices use the same proprietary technology to efficiently measure dark adaptatio
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the ARVO 2022 Annual Meetinghttps://modernod.com/news/meiragtx-presents-clinical-data-on-botaretigene-sparoparvovec-for-the-treatment-of-x-linked-retinitis-pigmentosa-at-the-arvo-2022-annual-meeting/2480844/MeiraGTx Holdings plc announced that additional clinical data from the phase 1/2 trial of botaretigene sparoparvovec for the treatment of x-linked retinitis pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colo
- SAV-IOL Launches Instant Focus EDOF IOL Technologyhttps://modernod.com/news/sav-iol-launches-instant-focus-edof-iol-technology/2480841/Instant Focus is a unique optical technology designed by Swiss IOL maker SAV-IOL (Swiss Advanced Vision). The technology is designed to replace the accommodative function of the eye’s natural lens after cataract surgery, and is manufactured and marketed directly from their he
- EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwanhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-expanded-license-agreement-with-betta-pharmaceuticals-for-eyp-1901-in-china-hong-kong-macau-and-taiwan/2480838/EyePoint Pharmaceuticals announced the execution of a license agreement with Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. This agreement expands the collaboration between EyePoint and Equinox Sciences, a Bet
- Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidatehttps://modernod.com/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate/2480829/Ashvattha Therapeutics announced the presentation of safety data from a phase 1 study of its lead candidate D-4517.2, a VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at ARVOhttps://modernod.com/news/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-product-for-the-treatment-of-pced-at-arvo/2480824/Kala Pharmaceuticals reported clinical data from a phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements